Mody, K. T. and Mahony, D. and Cavallaro, A. S. and Zhang, J. and Zhang, B. and Mahony, T. J. and Yu, C. Z. and Mitter, N. (2015) Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein. Plos One, 10 (12). p. 16. ISSN 1932-6203
Full text not currently attached. Access may be available via the Publisher's website or OpenAccess link.
Article Link(s): http://dx.doi.org/10.1371/journal.pone.0143507
Bovine Viral Diarrhoea Virus (BVDV) is one of the most serious pathogen, which causes tremendous economic loss to the cattle industry worldwide, meriting the development of improved subunit vaccines. Structural glycoprotein E2 is reported to be a major immunogenic determinant of BVDV virion. We have developed a novel hollow silica vesicles (SV) based platform to administer BVDV-1 Escherichia coli-expressed optimised E2 (oE2) antigen as a nanovaccine formulation. The SV-140 vesicles (diameter 50 nm, wall thickness 6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm(3)g(-1)) have proven to be ideal candidates to load oE2 antigen and generate immune response. The current study for the first time demonstrates the ability of freeze-dried (FD) as well as non-FD oE2/SV140 nanovaccine formulation to induce long-term balanced antibody and cell mediated memory responses for at least 6 months with a shortened dosing regimen of two doses in small animal model. The in vivo ability of oE2 (100 mu g)/SV-140 (500 mu g) and FD oE2 (100 mu g)/SV-140 (500 mu g) to induce long-term immunity was compared to immunisation with oE2 (100 mu g) together with the conventional adjuvant Quil-A from the Quillaja saponira (10 mu g) in mice. The oE2/SV-140 as well as the FD oE2/SV-140 nanovaccine generated oE2-specific antibody and cell mediated responses for up to six months post the final second immunisation. Significantly, the cell-mediated responses were consistently high in mice immunised with oE2/SV-140 (1,500 SFU/million cells) at the six-month time point. Histopathology studies showed no morphological changes at the site of injection or in the different organs harvested from the mice immunised with 500 mu g SV-140 nanovaccine compared to the unimmunised control. The platform has the potential for developing single dose vaccines without the requirement of cold chain storage for veterinary and human applications.
|Business groups:||Animal Science|
|Additional Information:||Mody, Karishma T. Mahony, Donna Cavallaro, Antonino S. Zhang, Jun Zhang, Bing Mahony, Timothy J. Yu, Chengzhong Mitter, Neena Queensland Government Research Partnership ; Queensland Alliance for Agriculture and Food Innovation, The University of Queensland The work was facilitated by a Queensland Government Research Partnership grant 2012001137. Karishma Mody's PhD was supported by Queensland Alliance for Agriculture and Food Innovation, The University of Queensland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 0 2 PUBLIC LIBRARY SCIENCE SAN FRANCISCO PLOS ONE|
|Keywords:||NANOPARTICLES VACCINE DELIVERY ANTIGEN BVDV STABILIZATION STABILITY ADJUVANTS Multidisciplinary Sciences|
|Subjects:||Veterinary medicine > Veterinary virology|
|Deposited On:||09 Feb 2016 02:07|
|Last Modified:||19 Jul 2016 05:35|
Repository Staff Only: item control page